---

Swiss multinational manufacturing company Lonza has inked a long-term commercial supply agreement with American biopharmaceutical company Vertex for manufacture of the CASGEVY (exagamglogene autotemcel).

Lonza, a Contract Development and Manufacturing Organization (CDMO), has footprints in cell and gene therapy, biologics, small molecules, capsules, and health ingredients. In this deal, the Swiss firm will leverage its experience in the commercial manufacture of cell therapeutics and regulatory and scientific expertise to bring CASGEVY to market.

“It is a privilege to work with Vertex on bringing its innovative and cutting-edge medicines to patients suffering from life-threatening diseases,” said Daniel Palmacci, President, Cell & Gene, Lonza.

---

READ ALSO: GSK receives Positive EU opinion for fully liquid meningococcal vaccine

---

The product, whose discoverers won a Nobel Prize in 2020, presents the possibility of a single treatment option for eligible patients struggling with sickle cell disease.

The "state-of-the-art” cGMP cell therapy manufacturing facilities in Geleen, Netherlands, will be the site of Lonza's CASGEVY® manufacturing operations, with expectation of expansion to its Portsmouth, US, location.

“The Lonza team have been excellent partners, as we have invested in our global manufacturing network to ensure CASGEVY® will be available for the patients who need it. We look forward to our continued collaboration,” stated Morrey Atkinson, Ph.D., Executive Vice President, Vertex.

---

Did you find this insightful? Subscribe for more.

---